C84.66 Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes

Name of the Condition

• Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes (ICD-10 Code: C84.66)

Summary

Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving the intrapelvic lymph nodes. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.

Causes

The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.

Risk Factors

• Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
• Gender: Slightly higher prevalence in males.
• Genetic factors: Presence of the ALK translocation is a primary risk factor.
• Immunosuppression: Weakened immune systems may increase risk.

Symptoms

Symptoms may include pain or swelling in the pelvic region, unexplained weight loss, fever, night sweats, or fatigue. Some patients may experience abdominal discomfort or changes in bowel or bladder function due to lymph node enlargement.

Diagnosis

Diagnosis typically involves a biopsy of the affected lymph node, followed by immunohistochemical staining to detect the ALK protein. Additional tests, such as flow cytometry, genetic analysis, or imaging (e.g., CT or PET scans), may be used to confirm the diagnosis and assess disease extent.

Treatment Options

Treatment often includes systemic therapies such as chemotherapy, targeted therapy (e.g., ALK inhibitors), or immunotherapy. Radiation therapy may be used for localized disease. Treatment plans are tailored to the patient’s age, overall health, and disease stage.

Prognosis and Follow-Up

Prognosis varies based on disease stage and response to treatment. ALK-positive ALCL generally has a better prognosis than ALK-negative subtypes, especially in younger patients. Regular follow-up with imaging and clinical evaluations is recommended to monitor for recurrence.

Complications

Complications may include tumor spread to other organs, treatment-related side effects (e.g., infection risk from chemotherapy), or long-term effects of therapy. Advanced disease can lead to organ dysfunction or reduced quality of life.

Lifestyle & Prevention

No specific preventive measures are known, as the cause is genetic. Maintaining a healthy immune system through balanced nutrition, regular exercise, and avoiding known immunosuppressants (when possible) may support overall health.

When to Seek Professional Help

Seek medical attention for persistent pelvic pain, unexplained weight loss, fever, or swollen lymph nodes. Early evaluation is important for timely diagnosis and treatment.

Tips for Medical Coders

Use C84.66 for anaplastic large cell lymphoma, ALK-positive, specifically involving intrapelvic lymph nodes. Ensure documentation specifies the ALK-positive status and the intrapelvic location to support accurate coding. Verify that the diagnosis aligns with histopathological and genetic findings to confirm code applicability.